Sunitinib in the Treatment of Thymoma and Associated Autoimmune Neutropenia.

[1]  N. Girard,et al.  Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. , 2016, Lung cancer.

[2]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[3]  Patricia Jones,et al.  Pure white cell aplasia in a patient with thymic carcinoma. , 2013, Blood.

[4]  S. Rangarajan,et al.  Acquired agranulocytosis and factor XI deficiency in association with thymoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Qiang Xu,et al.  Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. , 2010, Clinical immunology.

[6]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[7]  B. Rini,et al.  Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.

[8]  K. Ozawa,et al.  Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group , 2008, Haematologica.

[9]  C. Liang,et al.  SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity , 2006, Molecular Cancer Therapeutics.

[10]  M. Rowley,et al.  Remission induced by Campath-1H for thymoma-associated agranulocytosis , 2004, Annals of Hematology.

[11]  B. Borisch,et al.  Complete remission of pure white cell aplasia associated with thymoma, autoimmune thyroiditis and type 1 diabetes , 2003, European journal of haematology.

[12]  H. Müller-Hermelink,et al.  Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. , 2000, Blood.

[13]  J. Rasko,et al.  Thymoma and agranulocytosis: two case reports and literature review , 1996, British journal of haematology.

[14]  Makoto Kobayashi,et al.  The effect of thymectomy on myasthenia gravis, thrombocytopenia, and granulocytopenia associated with thymoma: Report of a case , 1995, Surgery Today.

[15]  David Stroncek,et al.  Immune mediated agranulocytosis and anemia associated with thymoma , 1995, American journal of hematology.

[16]  S. Ackland,et al.  White blood cell aplasia associated with thymoma. , 1988, American journal of clinical pathology.

[17]  T. Wallington,et al.  Pure red cell aplasia and thymoma associated with high levels of the suppressor/cytotoxic T lymphocyte subset. , 1984, British medical journal.

[18]  M. Housset,et al.  Syndrome of neutrophil agranulocytosis, hypogammaglobulinemia, and thymoma , 1982 .

[19]  R. Young,et al.  Thymoma with agranulocytosis and hypogammaglobulinaemia , 1977, Irish journal of medical science.

[20]  H. Frenzel,et al.  [Immunoglobulin deficiency syndrome and agranulocytosis in thyoma]. , 1967, Schweizerische medizinische Wochenschrift.

[21]  P. Mathieson,et al.  Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma: case report and literature review. , 1990, The Quarterly journal of medicine.

[22]  A. Weir,et al.  Response of agranulocytosis to thymectomy in a patient with thymoma and chronic lymphocytic leukemia. , 1989, Medical and pediatric oncology.